Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
New Managers March 2012

Perspectives
Opinions on emerging managers voiced in the last 30 days

Commentators this month noted on the plight of the Asia-focused emerging managers who cannot raise capital, on the new burdensome technological requirements that new hedge funds have to face, and on the benefits of being small and nimble.

Asia hedge funds shutting down

Asia-focused hedge funds that launched after the 2008 credit crisis are shutting down as a shrinking pool of key investors makes it harder for them to raise capital, said Bloomberg in early March, citing Isometric Investment Advisors and Black's Link Capital which decided to close shop after heavy investor withdrawals.

"All the smaller funds of funds who used to help and family wealth who used to help early managers grow are just not there," said Richard Johnston, Hong Kong-based Asia head of Albourne Partners Ltd., a consulting firm, told Bloomberg. "The gap between seed capital and getting to a good meaningful sustainable size of $500 million plus is a hard gap to plug."

Sadly, Hong Kong-based Triple A recently decided to discontinue its seeding activity due to a lack of investor appetite.

Learn more about Asian start-ups from our last issue of New Managers here: Source.

New technological requirements

New hedge funds, whether or not they manage to get seeding capital from the investment banks which are now venturing into this area, beware; new technological requirements and the post-2008 investment landscape mean the barriers to success are higher than ever, warned ......................

To view our full article please login

This article was published in Opalesque's New Managers a top-down monthly analysis, news and research publication on the global emerging manager space.
New Managers
New Managers
New Managers

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for